focus -WSS

focus

author：leisure time 2025-09-29 23:27:56 - browse：439

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Akero's treatment for NASH falls short in cirrhosis study

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Medicare bonuses could stop drug shortages under Senate plan

Mass General, Mayo Clinic look to monetize custom

What the Wegovy shortage looks like for doctors — and for patients

hotspot

focus

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Takeaways from AdvaMed, the largest medical devices conference

Moonlake's readout produced a cash windfall. Risks remain

Flu vaccine reformulation won't be easy, manufacturers warn

In Memoriam: Notable people who died in 2023

What the Wegovy shortage looks like for doctors — and for patients

Hepatitis C has a cure — but many Americans still lack access to it

Future doctors need a strong humanities education

Medicare proposal to cover medical devices draws a mixed reaction

CVS is on a mission to consolidate health care. Will it work?

entertainment

Medicare drug price lawsuits could be good politics for Biden

FDA endorses new sterilization method for medical devices

Cancer cells are shown to suck energy source from immune cells

High breast density mammograms need follow

CVS is on a mission to consolidate health care. Will it work?

Pumping milk in bathrooms at health conferences is common

hotspot

Wikipedia

explore

focus